Peptide bioregulators

Compounds in this category

14 of 15 entries are published. Compounds without a published entry are listed without a link. 1 compound is marked as having no indexed literature: below two independently verifiable sources this library publishes nothing rather than something thin.

• VilonVilon is the synthetic dipeptide Lys-Glu, the shortest member of the Khavinson bioregulator series and one of the few with a complete set of public register identifiers. Its literature is concentrated in one research programme and consists chiefly of cell-culture and rodent work, with two small uncontrolled human reports. It is not approved by the FDA for any indication.
• VesugenVesugen is the synthetic tripeptide Lys-Glu-Asp, the vascular member of the Khavinson bioregulator series, also published under the sequence label KED and the laboratory code T-38. Its literature is concentrated in one research programme and consists chiefly of endothelial cell culture, molecular docking and two small uncontrolled human reports. It is not approved by the FDA for any indication.
• Vesiluteno indexed literature
• ThymogenThymogen is the dipeptide L-alpha-glutamyl-L-tryptophan, isolated by chromatography from a calf thymus peptide complex and then synthesised. It is the only compound in the Khavinson bioregulator series with an International Nonproprietary Name and a registered clinical trial record, both of which belong to its disodium salt under the development code IM-862. It is not approved by the FDA for any indication.
• TestagenTestagen is the synthetic tetrapeptide Lys-Glu-Asp-Gly from the Khavinson bioregulator series. Its trade name assigns it to the male reproductive system, while its primary literature describes it as derived from anterior pituitary extract and studies it in the thyroid and thymus of hypophysectomised birds. No clinical study of it has been identified and it is not approved by the FDA for any indication.
• ProstamaxProstamax is the synthetic tetrapeptide Lys-Glu-Asp-Pro, the prostatic member of the Khavinson bioregulator series. Its published record is small and almost entirely cytogenetic and microcalorimetric work on lymphocytes cultured from elderly donors. No clinical study of it has been identified, and it is not approved by the FDA for any indication.
• PancragenPancragen is the C-terminally amidated tetrapeptide Lys-Glu-Asp-Trp, the pancreatic member of the Khavinson bioregulator series. It is the only compound in that series with published non-human primate studies, alongside rat work, pancreatic cell culture and one non-randomised human report. It is not approved by the FDA for any indication.
• LivagenLivagen is the synthetic tetrapeptide Lys-Glu-Asp-Ala, the hepatic member of the Khavinson bioregulator series. It is unusual within that series for having a measured enzyme-inhibition constant and a published negative receptor-binding control. No clinical study of it has been identified, and it is not approved by the FDA for any indication.
• CrystagenCrystagen is the synthetic tripeptide Glu-Asp-Pro, also published under the laboratory code T-36. It has the smallest published record of any compound in this batch — two primary papers, both in excised tissue — and the identification of its trade name with its sequence rests on a single review table. It is not approved by the FDA for any indication.
• CortagenCortagen is the synthetic tetrapeptide Ala-Glu-Asp-Pro, designed from the amino acid composition of the brain cortex preparation Cortexin. Its strongest primary evidence is a rat sciatic nerve regeneration study; no clinical report of it has been identified. It is not approved by the FDA for any indication.
• BronchogenBronchogen is the synthetic tetrapeptide Ala-Glu-Asp-Leu, the bronchial member of the Khavinson bioregulator series. It has a rat model of obstructive lung pathology behind it and, unusually for this family, direct physical measurements of its interaction with DNA. No clinical study of it has been identified, and it is not approved by the FDA for any indication.
• CardiogenCardiogen is the synthetic tetrapeptide Ala-Glu-Asp-Arg, the cardiac member of the Khavinson bioregulator series. Its name collides with two unrelated products, so its identifiers are reached by structure rather than by name. Its published record is a rat tumour study, organotypic myocardial culture and one cytoskeletal protein study; no clinical study of it has been identified.
• ChonlutenChonluten is the synthetic tripeptide Glu-Asp-Gly, published in most of its primary literature under the laboratory code T-34. At 319 daltons it is the smallest member of the Khavinson bioregulator series. Its identified record is three cell-culture and explant papers, one of which reports it as inactive where four siblings were active. It is not approved by the FDA for any indication.
• OvagenOvagen is the synthetic tripeptide Glu-Asp-Leu from the Khavinson bioregulator series, published in the primary literature only as the EDL peptide. Its entire identified primary record is two rat studies of acute kidney damage from one author group. No clinical study of it has been identified and it is not approved by the FDA for any indication.
• CartalaxCartalax is the synthetic tripeptide Ala-Glu-Asp, the cartilage member of the Khavinson bioregulator series, published mostly under the sequence label AED rather than its trade name. Its record is cell culture in chondrocytes, mesenchymal stem cells and dermal fibroblasts, plus one rat renal study. No clinical study of it has been identified and it is not approved by the FDA for any indication.